By end date
since
until
Due to illness
By entity
By state
By country
By Sponsor
Search by name
| |
|
Trail |
Sponsor |
Illness |
|
|
|
|
|
Phase I Clinical Study of Dose-escalation Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of Recombinant Anti-FGFR Human-mouse Chimeric Monoclonal Antibody Injection BK011 in Patients with Advanced Malignant Solid Tumors
Start: 18/5/2022
Recruitment:
Final:
Status:
In progress
|
Zhejiang Newind Biotechnology Co.
|
Esophageal Neoplasms; Stomach Neoplasms
|
|
|
|
|
|
|
|
|
|
|
Phase I/II Clinical Study of Mitoxantrone Hydrochloride Liposomes in Combination With Gemcitabine, Dexamethasone, and Cisplatin in Relapsed/Refractory Peripheral T-cell Lymphoma
Start: 1/5/2022
Recruitment:
Final:
Status:
In progress
|
Peking Union Medical College Hospital, CAMS
CSPC Pharmaceutical Group Co./CSPC Ouyi Pharmaceutical Co.
|
Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral
|
|
|
|
|
|
|
|
|
|
|
Single arm and single center clinical study on safety, tolerance and efficacy of GC101 injection in patients with type 1 spinal muscular atrophy
Start: 16/2/2022
Recruitment:
Final:
Status:
In progress
|
(Other Hospital/Academic/Medical Center)
GeneCradle
|
Spinal Muscular Atrophy
|
|
|
|
|
|
|
|
|
|
|
Clinical Study on the Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer
Start: 2/4/2021
Recruitment:
Final:
Status:
In progress
|
Shanghai Biomed-Union Biotechnology Co.
|
Pancreatic Neoplasms
|
|
|
|
|
|
|
|
|
|
|
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma
Start: 26/6/2022
Recruitment:
Final:
Status:
In progress
|
CASI Pharmaceuticals {EntreMed}
(Other Hospital/Academic/Medical Center)
|
Multiple Myeloma; Neoplasms, Plasma Cell
|
|
|
|
|
|
|
|
|
|
|
A Phase I study of ZS801 injection, an rAAV gene therapy drug of Sichuan Zhishan Weixin Biotechnology Co., Ltd., in hemophilia B subjects.
Start: 1/1/1900
Recruitment:
Final:
Status:
In progress
|
Sichuan Zhishan Weixin Biotechnology Co.
|
Blood Coagulation Disorders; Hemophilia B; Hemostatic Disorders
|
|
|
|
|
|
|
|
|
|
|
A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of Advanced/Metastatic Renal Cell Carcinoma
Start: 31/12/2021
Recruitment:
Final:
Status:
In progress
|
Chongqing Precision Biotech Co.
|
Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasm Metastasis; Wilms Tumor
|
|
|
|
|
|
|
|
|
|
|
This is a Phase I Clinical Study to Evaluate the Safety and Efficacy of CAR-T Infusion Preparation in the Treatment of CD19-positive Relapsed/Refractory Non-Hodgkin Lymphoma
Start: 6/9/2021
Recruitment:
Final:
Status:
In progress
|
Chongqing Precision Biotech Co.
|
Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin
|
|
|
|
|
|
|
|
|
|
|
An Open, Single-armed, Phase I Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Advanced Malignant Solid Tumors
Start: 14/6/2022
Recruitment:
Final:
Status:
In progress
|
Shanghai Gencells Therapeutics Co.
|
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Melanoma; Neoplasms; Uterine Cervical Neoplasms
|
|
|
|
|
|
|
|
|
|
|
A Phase I Clinical Study of Anti-CEA CAR-T Therapy in the Treatment of CEA-positive Advanced Malignant Solid Tumors
Start: 10/9/2021
Recruitment:
Final:
Status:
In progress
|
Chongqing Precision Biotech Co.
|
Colorectal Neoplasms; Esophageal Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Recurrence; Stomach Neoplasms
|
|
|
|
|
|
|
|
|
|